Gitnux/Report 2026

Neuromodulation Industry Statistics

The global neuromodulation devices market is estimated at $7.0 billion in 2026, explore the 2026–2033 growth path, company coverage, and technology trends.
22Statistics
28Sources
6Sections
1Visuals
15mRead
November 20, 2026Updated
Neuromodulation Industry Statistics
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The neuromodulation industry at a glance

The global neuromodulation devices market is estimated at $7.0 billion in 2026, with North America holding 43.4% of 2025 revenue and adaptive, closed-loop stimulation driving product development.

$7.0B[5]
2026 market estimate
10.4%[5]
2026–2033 forecast CAGR
43.4%[5]
North America share, 2025
42.8%[5]
Spinal cord stimulators share, 2025
Market size
The global neuromodulation devices market was valued at $6.4 billion in 2025 and is estimated at $7.0 billion in 2026. A separate market estimate places the broader neuromodulation market at $7.22 billion in 2026.[5][7]
Forecast & CAGR
Grand View Research forecasts the neuromodulation devices market to reach $13.9 billion by 2033, representing a 10.4% CAGR from 2026 to 2033. Mordor Intelligence forecasts the broader market to reach $10.93 billion by 2031 at an 8.65% CAGR from 2026 to 2031.[5][7]
Market share & regions
North America accounted for 43.4% of global neuromodulation devices revenue in 2025, making it the largest regional market. The United States accounted for 36.0% of global neuromodulation devices revenue in 2025 in one country-level estimate.[5][12]
Segmentation
Spinal cord stimulators were the largest product segment, representing 42.8% of market revenue in 2025. The market is also segmented into deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, peripheral nerve stimulation and non-invasive modalities such as transcranial magnetic stimulation.[5][7]
Key players & concentration
The principal commercial competitors include Medtronic, Boston Scientific, Abbott, Nevro, LivaNova and BIOTRONIK. Mordor Intelligence characterizes market concentration as medium; no reliable source reviewed provided a directly comparable combined share for the leading companies.[7][5]
Pricing
A 2025 International Pain and Spine Intervention Society summary reported average insurer costs of $55,635 for spinal cord stimulation, including the device, medical and hospital costs for the initial procedure and re-interventions. An Ontario evidence review estimated approximately $34,660 in total five-year costs for 10-kHz spinal cord stimulation, including device costs.[13][14]
Trends, drivers & challenges
Growth is being supported by neurological disease prevalence, demand for minimally invasive treatment and advances in sensing and closed-loop stimulation. Boston Scientific estimated the 2025 served market at approximately $2.5 billion for spinal cord stimulation and $1.0 billion for deep brain stimulation, while competition from non-invasive tools remains a challenge.[5][15][16]
Consumer behavior & competition
Demand is concentrated in chronic pain and movement-disorder treatment, with providers increasingly adopting systems that personalize stimulation. The competitive landscape includes established implantable-device manufacturers and newer peripheral-nerve and wearable-stimulation companies; no reliable source reviewed provided a comparable global patient or consumer adoption rate.[5][7]
M&A
M&A activity has expanded neuromodulation portfolios: Globus Medical agreed to acquire Nevro for approximately $250 million in 2025, Boston Scientific agreed to acquire Nalu Medical for approximately $533 million in 2025, and Boston Scientific completed the Nalu acquisition in January 2026 for approximately $523 million net of cash acquired.[17][18]
Regulation
The U.S. FDA approved an adaptive deep brain stimulation programming feature for Medtronic’s Activa, Percept and SenSight systems on February 20, 2025. The approval covers bilateral stimulation of the globus pallidus or subthalamic nucleus for specified patients with levodopa-responsive Parkinson’s disease.[10]
Latest news
In 2026, Boston Scientific completed its acquisition of Nalu Medical for approximately $523 million net of cash acquired, integrating the business into its Neuromodulation division. Medtronic also completed its acquisition of SPR Therapeutics in July 2026, adding temporary peripheral nerve stimulation technology for chronic and acute pain.[17][19]

02 Ranking

Top 10 Companies in the Neuromodulation Industry

The leading companies in the neuromodulation industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Boston Scientific stands out for neuromodulation devices covering movement disorders and chronic pain because it had an 18% operating margin in 2025, while BrainsWay focuses on Deep TMS for psychiatric indications since it commercializes systems cleared for depression, OCD, and smoking cessation.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in deep brain stimulation

    Boston Scientific

    US

    Ranked #1 · 9.4 · Deep brain stimulation

    Why we picked it: Its neuromodulation business develops devices for movement disorders and chronic pain with an 18% operating margin in 2025.

  2. Leader in noninvasive brain stimulation

    BrainsWay

    IL

    Ranked #2 · 8.9 · Noninvasive brain stimulation

    Why we picked it: It commercializes Deep TMS systems cleared for depression, OCD, smoking cessation and related indications.

  3. Leader in sacral neuromodulation

    Medtronic

    IE

    Ranked #3 · 8.6 · Sacral neuromodulation

    Why we picked it: It reports a dedicated Neuromodulation operating unit spanning pain, brain and pelvic-health therapies.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the neuromodulation industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Boston Scientific

Deep brain stimulation · US

9.4
2

BrainsWay

Noninvasive brain stimulation · IL

8.9
3

Medtronic

Sacral neuromodulation · IE

8.6
4

SetPoint Medical

Vagus-nerve stimulation · US

8.3
5

LivaNova

Vagus-nerve stimulation · GB

8.2
6

Saluda Medical

Closed-loop spinal cord stimulation · AU

8.1
7

NeuroPace

Responsive brain stimulation for epilepsy · US

8.0
8

Inspire Medical Systems

Implantable upper-airway stimulation for OSA · US

8.0
9

Mainstay Medical

Implantable restorative neurostimulation for back pain · IE

7.9
10

electroCore

Noninvasive vagus-nerve stimulation · US

7.6

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Margot Villeneuve. (2026, February 13). Top 10 companies in the neuromodulation industry. In Neuromodulation Industry Statistics. Gitnux. https://gitnux.org/neuromodulation-industry-statistics/#top-companies

report visual · Comparison

Revenue of the largest neuromodulation companies

Medtronic leads with $36.4B in annual revenue (group level, converted to USD).

Medtronic$36.4B
Boston Scientific$20.1B
LivaNova$1.4B
Inspire Medical Systems$912M
NeuroPace$100M
BrainsWay$52M
source-verifiednews.medtronic.com · bostonscientific.com · sec.gov2026

04 Statistics

Technology

The technology section quantifies patent pipelines and issued holdings, including Nevro’s 115 pending applications as of December 31, 2024 and 294 issued patents globally held by Nevro.

R&D, patents and design rights in the neuromodulation industry

  • 115 patent applications were pending globally for Nevro as of December 31, 2024, including 49 U.S. applications and 66 PCT or foreign applications.[1]
  • 779 neurotechnology patents, including neuromodulation and modulation-related inventions, were identified in a 2025 landscape using the study’s patent-search methodology; 39 patents raised ethical concerns.[2]
  • 294 issued patents were held globally by Nevro as of December 31, 2024, covering spinal-cord-stimulation systems and other neuromodulation technologies.[1]

05 Statistics

Market Intelligence

The market-intelligence section ties multiple market definitions to sizing and forecasting, including $7.0 billion for neuromodulation devices in 2026 and a $13.9 billion 2033 forecast.

Market size, volume and shipments in the neuromodulation industry

  • USD 7.11 billion was the estimated global neuromodulation market size in 2025, covering internal and external neuromodulation technologies, applications, end users and regions.[3]
  • USD 7.2 billion was the estimated global neuromodulation market size in 2024, covering neuromodulation devices and related technologies as defined by Market Glass.[4]
  • USD 6.4 billion was the estimated global neuromodulation-devices market size in 2025, covering spinal cord, deep brain and sacral nerve stimulators and related devices.[5]
  • USD 6.81 billion was the estimated global neuromodulation market size in 2025, based on MarketsandMarkets' category definition covering technology, stimulation type, application and end user.[6]

Forecast growth and shipments in the neuromodulation industry

  • The global neuromodulation market is forecast to reach USD 10.68 billion by 2030 from USD 6.81 billion in 2025, implying 9.4% CAGR for 2025–2030.[6]
  • The global neuromodulation-devices market is forecast to reach USD 13.9 billion by 2033 from USD 7.0 billion in 2026, implying 10.4% CAGR for 2026–2033.[5]
  • The global neuromodulation market is forecast to reach USD 10.93 billion by 2031 from USD 7.22 billion in 2026, implying 8.65% CAGR for 2026–2031.[7]

06 Statistics

Strategy & Growth

The strategy-and-growth section reports transaction volume and disclosed value in the broader segment, and it documents neuromodulation portfolio consolidation via announced and completed acquisitions.

M&A and consolidation in the neuromodulation industry

  • 548 transactions, including 98 M&A deals, were recorded in the broader cardiovascular, neuromodulation and robotics medtech segment in 2024; the source includes deals with undisclosed values.[8]
  • $38 billion in disclosed transaction value, including $31.5 billion of M&A value, was recorded in the broader cardiovascular, neuromodulation and robotics medtech segment in 2024.[8]
  • $3.7 billion was the 2024 acquisition value for Axonics, a sacral-neuromodulation-device company, acquired by Boston Scientific.[9]

07 Statistics

Product & Standards

The product-and-standards section lists FDA-recognized standards, including ISO 14708-3:2017 and IEC 60601-2-10 Edition 2.2 with FDA recognition entered in May 2025.

Standards, grades and specs for neuromodulation

  • ISO 14708-3:2017 is FDA-recognized as a complete standard for active implantable medical devices intended for electrical stimulation of the central or peripheral nervous system; U.S. recognition entered June 7, 2018.[10]
  • IEC 60601-2-10 Edition 2.2, dated January 2023, received complete FDA recognition on May 26, 2025 for basic safety and essential performance of nerve and muscle stimulators.[10]
  • ANSI/AAMI NS4:2013(R)2017 is FDA-recognized as a complete standard for transcutaneous electrical nerve stimulators, with U.S. recognition entered January 14, 2019.[10]

08 Statistics

Customers & Channel

The customers-and-channel section assigns external-neuromodulation device demand by setting, with hospitals at 42.1% of the 2025 global external-neuromodulation market value.

Demand by end use for neuromodulation

  • 42.1% of the 2025 global external-neuromodulation device market was attributed to hospitals, measured by market value; the category includes TENS, TMS, VNS and other external devices.[11]
  • 31.7% of the 2025 global external-neuromodulation device market was attributed to clinics, measured by market value; the category includes TENS, TMS, VNS and other external devices.[11]
  • US hospitals and ambulatory surgery centers represented $1,992.4 million of neuromodulation-device demand in 2023, measured by market value; the report segments neuromodulation devices by end-user setting.[6]

09 Statistics

Regulation & Risk

The regulation-and-risk section tracks FDA-listed recall activity for totally implanted spinal-cord stimulators under product code LGW, down from 5 in 2024 to 3 in 2026.

Recalls and safety notices for neuromodulation

  • 14 FDA-classified recalls were posted for totally implanted spinal-cord stimulators under product code LGW in the United States during 2024–2026, down from 5 in 2024 to 3 in 2026; the classification covers a core neuromodulation-device segment.[10]
  • 12 of 25 FDA-listed recalls for totally implanted spinal-cord stimulators under product code LGW were posted by Medtronic Neuromodulation, compared with 7 by Boston Scientific Neuromodulation and 3 by Abbott Medical, through November 16, 2026.[10]
  • 134 Nalu neurostimulation-system units were in commerce in a U.S. nationwide Class II recall posted October 29, 2026, after a firmware issue could make the therapy disc non-functional.[10]

Key questions about the Neuromodulation Industry

What is the size of the global neuromodulation devices market in 2026?
The global neuromodulation devices market is estimated at $7.0 billion in 2026.
How fast is the neuromodulation devices market forecast to grow after 2026?
The 2026–2033 forecast is a 10.4% CAGR, with the devices market reaching $13.9 billion by 2033.
Which companies lead the neuromodulation industry?
Boston Scientific stands out for neuromodulation devices covering movement disorders and chronic pain because it had an 18% operating margin in 2025, while BrainsWay focuses on Deep TMS for psychiatric indications since it commercializes systems cleared for depression, OCD, and smoking cessation.
What technology shift is most associated with new product development in neuromodulation devices?
Adaptive, closed-loop stimulation is driving product development, supported by advances in sensing and closed-loop stimulation.
How is the market distributed by region and by product segment?
North America held 43.4% of 2025 revenue, and spinal cord stimulators were 42.8% of market revenue in 2025.
What reimbursement economics are reported for spinal cord stimulation in the U.S.?
A 2025 International Pain and Spine Intervention Society summary reported average insurer costs of $55,635 for spinal cord stimulation, including initial procedure and re-interventions.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Margot Villeneuve. (2026, February 13). Neuromodulation Industry Statistics. Gitnux. https://gitnux.org/neuromodulation-industry-statistics
MLA
Margot Villeneuve. "Neuromodulation Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/neuromodulation-industry-statistics.
Chicago
Margot Villeneuve. 2026. "Neuromodulation Industry Statistics." Gitnux. https://gitnux.org/neuromodulation-industry-statistics.